EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY 4.0

Trends in Real-World Clinical Outcomes of Patients with Anaplastic Lymphoma Kinase (ALK) Rearranged Non-Small Cell Lung Cancer (NSCLC) Receiving One or More ALK Tyrosine Kinase Inhibitors (TKIs): A Cohort Study in Ontario, Canada

Lara Chayab iD, Natasha B Leighl, Mina Tadrous, Christine M Warren, William W L Wong

Current Oncology · 2024

DOI: 10.3390/curroncol32010013 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Current Oncology, 2024. Verfasst von Lara Chayab und 4 weiteren Autor:innen. Beteiligte Einrichtung: Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, ON M5S 3M2, Canada. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Anaplastic Lymphoma Kinase, Lung Neoplasms, Protein Kinase Inhibitors. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 80 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: non-industrial sponsor in University of Toronto / University Health Network, Toronto Health Economics and Technology Assessment THETA Collaborative.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The treatment landscape for patients with advanced ALK-positive NSCLC has rapidly evolved following the approval of several ALK TKIs in Canada. However, public funding of ALK TKIs is mostly limited to the first line treatment setting. Using linked provincial health administrative databases, we examined real-world outcomes of patients with advanced ALK-positive NSCLC receiving ALK TKIs in Ontario between 1 January 2012 and 31 December 2021. Demographic, clinical characteristics and treatment patterns were summarized using descriptive statistics. Kaplan–Meier analysis was performed to evaluate progression-free survival (PFS) and overall survival (OS) among the treatment groups. A total of 413 patients were identified. Patients were administered alectinib (n = 154), crizotinib (n = 80), or palliative-intent chemotherapy (n = 55) in the first-line treatment. There was a significant difference in first-line PFS between the treatment groups. The median PFS (mPFS) was not reached for alectinib (95% CI, 568 days—not reached), compared to 8.2 months (95% CI, 171–294 days) for crizotinib (HR = 0.34, p < 0.0001) and 2.4 months (95% CI, 65–100 days) for chemotherapy (HR = 0.14, p < 0.0001). There was no significant difference in first-line OS between the treatment groups. In patients who received more than one line of treatment, there was a significant difference in mOS between patients who received two or more lines of ALK TKIs compared to those who received one line of ALK TKI (mOS = 55 months (95% CI, 400–987 days) and 26 months (95% CI, 1448–2644 days), respectively, HR = 4.64, p < 0.0001). This study confirms the effectiveness of ALK TKIs in real-world practice and supports the potential benefit of multiple lines of ALK TKI on overall survival in patients with ALK-positive NSCLC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungAnaplastic Lymphoma KinaseLung NeoplasmsProtein Kinase InhibitorsHumansFemaleMaleMiddle AgedAgedAdultOntarioCrizotinibCohort StudiesTreatment OutcomeAged, 80 and overCarbazolesTyrosine Kinase InhibitorsPiperidines

Stichwörter der Autor:innen

ALK TKIsALK inhibitorsNSCLCOntario Canadaalectinibcrizotinibfirst line treatmentlung cancerreal-world outcomessequential treatment

Substanzen

Anaplastic Lymphoma KinaseProtein Kinase InhibitorsALK protein, humanCrizotinibalectinibCarbazolesTyrosine Kinase InhibitorsPiperidines

Autor:innen und Institutionen

  • Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, ON M5S 3M2, Canada.
  • Princess Margaret Cancer Centre, Toronto, ON M5G 2M9, Canada.
  • Department of Medicine, University of Toronto, Toronto, ON M5S 3M2, Canada.
  • Women's College Research Institute, Toronto, ON M5G 1N8, Canada.
  • ICES, Toronto, ON M4N 3M5, Canada.
  • School of Pharmacy, University of Waterloo, Waterloo, ON N2L 3G1, Canada.

ORCID-Profile: Lara Chayab

Förderung

  • non-industrial sponsor in University of Toronto / University Health Network
  • Toronto Health Economics and Technology Assessment THETA Collaborative

Zitieren

APA

Chayab, L., Leighl, N. B., Tadrous, M., Warren, C. M., & Wong, W. W. L. (2024). Trends in Real-World Clinical Outcomes of Patients with Anaplastic Lymphoma Kinase (ALK) Rearranged Non-Small Cell Lung Cancer (NSCLC) Receiving One or More ALK Tyrosine Kinase Inhibitors (TKIs): A Cohort Study in Ontario, Canada. Current Oncology. https://doi.org/10.3390/curroncol32010013

Vancouver

Chayab L, Leighl NB, Tadrous M, Warren CM, Wong WWL. Trends in Real-World Clinical Outcomes of Patients with Anaplastic Lymphoma Kinase (ALK) Rearranged Non-Small Cell Lung Cancer (NSCLC) Receiving One or More ALK Tyrosine Kinase Inhibitors (TKIs): A Cohort Study in Ontario, Canada. Current Oncology. 2024. doi:10.3390/curroncol32010013

BibTeX
@article{Chayab2024,
  author = {Chayab, Lara and Leighl, Natasha B and Tadrous, Mina and Warren, Christine M and Wong, William W L},
  title = {Trends in Real-World Clinical Outcomes of Patients with Anaplastic Lymphoma Kinase (ALK) Rearranged Non-Small Cell Lung Cancer (NSCLC) Receiving One or More ALK Tyrosine Kinase Inhibitors (TKIs): A Cohort Study in Ontario, Canada},
  journal = {Current Oncology},
  year = {2024},
  doi = {10.3390/curroncol32010013}
}
Kostenlos starten →